HSP90AA1 and cancer: AUY-922 (luminespib) is a resorcinol-based inhibitor that was originally developed for cancer treatment and reached Phase II clinical trials (Felip et al. 2018), while geldanamycin is an ansamycin antibiotic natural product that has served as a prototype HSP90 inhibitor.